The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a…
Articles by Patricia Inácio, PhD
Anima Biotech has partnered with Takeda Pharmaceuticals to develop small molecules that control mRNA translation — the process…
A Phase 1 trial will evaluate PTC Therapeutic’s PTC518, its investigational therapy for Huntington’s disease, in healthy…
The U.S. Food and Drug Administration (FDA) is putting on hold Voyager Therapeutics’ request to test VY-HTT01,…
The first patients have been enrolled in a clinical study of the natural history of Huntington’s disease (HD) and…
AFFiRiS’ C6-17, a candidate monoclonal antibody for the treatment of Huntington’s disease, is able to target and halt the spread…
A Phase 1/2 clinical trial evaluating AMT-130 as a potential gene therapy for Huntington’s disease has “treated” its first two patients,…
Vaccinex’s Phase 2 SIGNAL study, evaluating the investigational antibody pepinemab (VX15/2503) in Huntington’s disease patients with late…
Roche has completed patient enrollment for its Phase 3 GENERATION HD1 clinical trial evaluating the potential of tominersen to delay…
A Phase 1 clinical trial testing Roche’s investigational therapy tominersen for Huntington’s disease has been…